148 related articles for article (PubMed ID: 22972527)
1. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
Saadoun D; Pineton de Chambrun M; Hermine O; Karras A; Choquet S; Jego P; Decaux O; Cacoub P
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):643-7. PubMed ID: 22972527
[TBL] [Abstract][Full Text] [Related]
2. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
Ferrario A; Pulsoni A; Olivero B; Rossi G; Vitolo U; Tedeschi A; Merli F; Rigacci L; Stelitano C; Goldaniga M; Mannina D; Musto P; Rossi F; Gamba E; Baldini L
Cancer; 2012 Aug; 118(16):3954-61. PubMed ID: 22179904
[TBL] [Abstract][Full Text] [Related]
5. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M
Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
[TBL] [Abstract][Full Text] [Related]
7. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
8. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
11. Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Guo B; Zhu HL; Fan H; Li SX; Lu XC; Lin J; Ran HH; Zhai B; Yang Y
Adv Ther; 2012 Feb; 29(2):178-86. PubMed ID: 22249944
[TBL] [Abstract][Full Text] [Related]
12. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.
Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M
Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494
[TBL] [Abstract][Full Text] [Related]
13. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia.
Wiernik PH; Adiga GU
Curr Med Res Opin; 2011 Oct; 27(10):1987-93. PubMed ID: 21905969
[TBL] [Abstract][Full Text] [Related]
14. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Zagoskina TP; Tkachenko SB; Golubeva ME; Kudriavtseva AV; Isaeva NV; Malykh OV
Ter Arkh; 2010; 82(1):35-9. PubMed ID: 20364698
[TBL] [Abstract][Full Text] [Related]
20. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]